Forte Biosciences director awarded 18,353 RSUs

VINCENT RICHARD G reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

VINCENT RICHARD G reported acquisition or exercise transactions in this Form 4 filing.

Forte Biosciences, Inc. director Richard G. Vincent received a grant of 18,353 restricted stock units (RSUs), each representing a contingent right to one share of common stock. All RSUs will vest in full at the first annual stockholder meeting occurring after May 29, 2026, if he continues as a service provider.

Insider Trade Summary

Grant/Award: 18,353 shares

Grant/Award 1 txn

Insider VINCENT RICHARD G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,353	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 18,353 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
2. F2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

Key Figures

RSUs granted: 18,353 units Exercise price: $0.00 per unit Holdings after grant: 18,353 RSUs

3 metrics

RSUs granted 18,353 units Restricted Stock Units granted on May 29, 2026

Exercise price $0.00 per unit RSU grant to Richard G. Vincent

Holdings after grant 18,353 RSUs Total restricted stock units following transaction

Key Terms

Restricted Stock Units, contingent right, Service Provider, 2021 Equity Incentive Plan

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock"

Service Provider financial

"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan)"

2021 Equity Incentive Plan financial

"Service Provider (as defined in the 2021 Equity Incentive Plan) through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Forte Biosciences (FBRX) report for Richard G. Vincent?

Forte Biosciences reported that director Richard G. Vincent received a grant of 18,353 restricted stock units. Each RSU represents a contingent right to one share of Forte Biosciences common stock, awarded as part of the company’s equity-based compensation.

How many Forte Biosciences (FBRX) RSUs were granted in this Form 4 filing?

The filing shows a grant of 18,353 restricted stock units to director Richard G. Vincent. These RSUs currently carry a zero-dollar exercise price and convert into an equal number of Forte Biosciences common shares when they vest, subject to service conditions.

When do Richard G. Vincent’s Forte Biosciences (FBRX) RSUs vest?

All 18,353 RSUs vest 100% on the date of the first annual meeting of stockholders occurring after May 29, 2026. Vesting requires that Richard G. Vincent continue as a service provider under the company’s 2021 Equity Incentive Plan through that meeting date.

What does each Forte Biosciences (FBRX) RSU represent in this grant?

Each restricted stock unit represents a contingent right to receive one share of Forte Biosciences common stock. The units do not require a purchase price; instead, they convert into shares if the vesting conditions and continued service requirements are satisfied under the plan.

Is this Forte Biosciences (FBRX) Form 4 a stock purchase or a compensation award?

This Form 4 reflects a compensation-related award, not a market purchase. Director Richard G. Vincent received 18,353 restricted stock units as a grant with a stated price of $0.00 per unit, subject to future vesting linked to continued service with Forte Biosciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VINCENT RICHARD G

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BUILDING 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		A		18,353		(2)	(2)	Common Stock	18,353	$0	18,353	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)